Easier Access For Ranitidine Liquid – PHARMAC

PHARMAC is making it easier for patients to access the liquid form of the stomach ulcer and heartburn drug ranitidine.

From March 1, Ranitidine oral liquid’s special authority access criteria will be removed and it will become available from retail pharmacies.

Ranitidine (brand name Zantac) is prescribed for the treatment and prevention of stomach and duodenal ulcers, and for the treatment of conditions like heartburn and gastric reflux.

Ranitidine is already fully subsidised in its tablet, oral liquid and injection forms, although doctors of those patients requiring the oral liquid need to complete special authority forms.

Though the special authority access criteria will be removed, ranitidine oral liquid will continue to be targeted at those people who have problems swallowing tablets, such as children or patients in terminal care, through the use of prescription endorsement.

PHARMAC Chief Executive Wayne McNee says patients requiring the liquid form of this drug, aimed primarily at children and the elderly, will be able to pick up their prescription from a retail pharmacy.

“We are pleased to be able to offer this form of medication more widely, and to improve accessibility.

“For some people swallowing tablets is a real issue. Removing the special authority on ranitidine oral liquid will make it easier for patients and prescribers to decide on this form of the drug, and making it available from retail pharmacies will make it easier for them to collect their prescriptions.’’

[ends]

© Scoop Media